Effect of repeated exposure to MDMA on the function of the 5-HT transporter as assessed by synaptosomal 5-HT uptake

Brain Research Bulletin

Volumn 91, Issue , 2013, Pages 52-57

  Huff, Courtney ^a   Bhide, Nirmal ^a   Schroering, Allen ^b   Yamamoto, Bryan K ^b   Gudelsky, Gary A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

MDMA; Serotonin; Serotonin transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DOWN REGULATION; ENDOSOME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; IMMUNOREACTIVITY; LONG TERM CARE; MALE; MICRODIALYSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; SEROTONIN UPTAKE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALLUCINOGENS; MALE; MICRODIALYSIS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTOSOMES;

EID: 84873710587     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2013.01.003     Document Type: Article

References (34)

1. Aguirre N., Ballaz S., Lasheras B., Del Rio J. MDMA ('ecstasy') enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. European Journal of Pharmacology 1998, 346:181-188.
2. Asano S., Matsuda T., Nakasu Y., Maeda S., Nogi H., Baba A. Inhibition by nitric oxide of the uptake of [3H]serotonin into rat brain synaptosomes. Japanese Journal of Pharmacology 1997, 75:123-128.
3. Battaglia G., Yeh S.Y., O'Hearn E., Molliver M.E., Kuhar M.J., De Souza E.B. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics 1987, 242:911-916.
4. Bhide N.S., Lipton J.W., Cunningham J.I., Yamamoto B.K., Gudelsky G.A. Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain. Brain Research 2009, 1286:32-41.
5. Biezonski D.K., Meyer J.S. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity. Journal of Neurochemistry 2010, 112:951-962.
6. Biezonski D.K., Meyer J.S. The nature of 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: evidence for and against the neurodegeneration hypothesis. Current Neuropharmacology 2011, 9:84-90.
7. Colado M.I., Green A.R. The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. European Journal of Pharmacology 1995, 280:343-346.
8. Colado M.I., O'Shea E., Granados R., Murray T.K., Green A.R. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. British Journal of Pharmacology 1997, 121:889-900.
9. Darvesh A.S., Yamamoto B.K., Gudelsky G.A. Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain. Journal of Pharmacology and Experimental Therapeutics 2005, 312:694-701.
10. German C.L., Hanson G.R., Fleckenstein A.E. Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. Journal of Neurochemistry 2012, 123:288-297.
11. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, " ecstasy" ). Pharmacological Reviews 2003, 55:463-508.
12. Gudelsky G.A. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. Journal of Neural Transmission 1996, 103:1397-1404.
13. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. Journal of Neurochemistry 1996, 66:243-249.
14. Jones D.C., Lau S.S., Monks T.J. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. Journal of Pharmacology and Experimental Therapeutics 2004, 311:298-306.
15. Kitagawa K., Matsumoto M., Kuwabara K., Tagaya M., Ohtsuki T., Hata R., Ueda H., Handa N., Kimura K., Kamada T. 'Ischemic tolerance' phenomenon detected in various brain regions. Brain Research 1991, 561:203-211.
16. Kittler K., Lau T., Schloss P. Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. European Journal of Pharmacology 2010, 629:63-67.
17. Kivell B., Day D., Bosch P., Schenk S., Miller J. MDMA causes a redistribution of serotonin transporter from the cell surface to the intracellular compartment by a mechanism independent of phospho-p38-mitogen activated protein kinase activation. Neuroscience 2010, 168:82-95.
18. Kramer H.K., Poblete J.C., Azmitia E.C. Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter. Neuropsychopharmacology 1997, 17:117-129.
19. Malberg J.E., Sabol K.E., Seiden L.S. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. Journal of Pharmacology and Experimental Therapeutics 1996, 278:258-267.
20. Mark K.A., Quinton M.S., Russek S.J., Yamamoto B.K. Dynamic changes in vesicular glutamate transporter 1 function and expression related to methamphetamine-induced glutamate release. Journal of Neuroscience 2007, 27:6823-6831.
21. Peraile I., Torres E., Mayado A., Izco M., Lopez-Jimenez A., Lopez-Moreno J.A., Colado M.I., O'Shea E. Dopamine transporter down-regulation following repeated cocaine: implications for 3,4-methylenedioxymethamphetamine-induced acute effects and long-term neurotoxicity in mice. British Journal of Pharmacology 2010, 159:201-211.
22. Piper B.J., Vu H.L., Safain M.G., Oliver A.J., Meyer J.S. Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist. Journal of Pharmacology and Experimental Therapeutics 2006, 317:838-849.
23. Piper B.J., Ali S.F., Daniels L.G., Meyer J.S. Repeated intermittent methylenedioxymethamphetamine exposure protects against the behavioral and neurotoxic, but not hyperthermic, effects of an MDMA binge in adult rats. Synapse 2010, 64:421-431.
24. Qian Y., Galli A., Ramamoorthy S., Risso S., DeFelice L.J., Blakely R.D. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. Journal of Neuroscience 1997, 17:45-57.
25. Renoir T., Paizanis E., El Yacoubi M., Saurini F., Hanoun N., Melfort M., Lesch K.P., Hamon M., Lanfumey L. Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice. International Journal of Neuropsychopharmacology 2008, 11:1149-1162.
26. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics 1987, 240:1-7.
27. Schmidt C.J., Taylor V.L. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochemical Pharmacology 1987, 36:4095-4102.
28. Shankaran M., Yamamoto B.K., Gudelsky G.A. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. European Journal of Pharmacology 1999, 385:103-110.
29. Shankaran M., Yamamoto B.K., Gudelsky G.A. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 2001, 40:55-64.
30. Shulgin A.T. The background and chemistry of MDMA. Journal of Psychoactive Drugs 1986, 18:291-304.
31. Steiner J.A., Carneiro A.M., Blakely R.D. Going with the flow: trafficking-dependent and -independent regulation of serotonin transport. Traffic 2008, 9:1393-1402.
32. Stone D.M., Stahl D.C., Hanson G.R., Gibb J.W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. European Journal of Pharmacology 1986, 128:41-48.
33. Xie T., Tong L., McLane M.W., Hatzidimitriou G., Yuan J., McCann U., Ricaurte G. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 2006, 31:2639-2651.
34. Yamamoto B.K., Moszczynska A., Gudelsky G.A. Amphetamine toxicities: classical and emerging mechanisms. Annals of the New York Academy of Sciences 2010, 1187:101-121.